

# REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:  
File Information Unit  
Crystal Plaza Three, Room 1001  
2021 South Clark Place  
Arlington, VA  
Telephone: (703) 305-2733

RECEIVED

AUG 24 2005

File Information Unit

In re Application of

Application Number

09/256,388

Filed

2/24/99

Paper No.

#11

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. \_\_\_\_\_, page, \_\_\_\_\_ line \_\_\_\_\_

United States Patent Number 6,537,549, column \_\_\_\_\_, line, \_\_\_\_\_ or

WIPO Pub. No. \_\_\_\_\_, page \_\_\_\_\_, line \_\_\_\_\_

## Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:  
For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:

- the pending application as originally filed.

R. Mitchell

Signature

R. Mitchell

Typed or printed name

Registration Number, if applicable

703-415-0100

Telephone Number

8/24/05

Date

FOR PTO USE ONLY

Emily [Signature]

Approved by:

AUG 24 2005

Unit

File Information Unit



US006537549B2

(12) **United States Patent**  
**Tobinick**

(10) **Patent No.:** **US 6,537,549 B2**  
 (45) **Date of Patent:** **\*Mar. 25, 2003**

(54) **CYTOKINE ANTAGONISTS FOR THE  
 TREATMENT OF LOCALIZED DISORDERS**

(76) **Inventor:** **Edward L. Tobinick, 100 UCLA  
 Medical Plaza, Suite 205, Los Angeles,  
 CA (US) 90024-6903**

(\*) **Notice:** **Subject to any disclaimer, the term of this  
 patent is extended or adjusted under 35  
 U.S.C. 154(b) by 0 days.**

**This patent is subject to a terminal dis-  
 claimer.**

(21) **Appl. No.:** **09/841,844**

(22) **Filed:** **Apr. 25, 2001**

(65) **Prior Publication Data**

US 2001/0026801 A1 Oct. 4, 2001

#### **Related U.S. Application Data**

(63) **Continuation-in-part of application No. 09/826,976, filed on  
 Apr. 5, 2001, now Pat. No. 6,419,944, which is a continu-  
 ation-in-part of application No. 09/563,651, filed on May 2,  
 2000, now Pat. No. 6,471,961, which is a continuation-in-  
 part of application No. 09/476,643, filed on Dec. 31, 1999,  
 now Pat. No. 6,177,077, which is a continuation-in-part of  
 application No. 09/275,070, filed on Mar. 23, 1999, now Pat.  
 No. 6,015,557, which is a continuation-in-part of application  
 No. 09/256,388, filed on Feb. 24, 1999, now abandoned.**

(51) **Int. Cl.<sup>7</sup>** ..... **A61K 39/42**

(52) **U.S. Cl.** ..... **424/134.1; 424/400; 424/422;  
 424/427; 424/434; 574/362; 574/363; 574/364**

(58) **Field of Search** ..... **424/400, 134.1,  
 424/422, 434, 427; 514/362, 363, 364**

(56) **References Cited**

#### **U.S. PATENT DOCUMENTS**

5,605,690 A \* 2/1997 Jacobs et al. .... 424/134.1  
 5,656,272 A \* 8/1997 Le et al. .... 424/133.1  
 6,015,557 A \* 1/2000 Tobinick et al. .... 424/134.1  
 6,177,077 B1 \* 1/2001 Tobinick et al. .... 424/134.1  
 6,180,355 B1 \* 1/2001 Alexander et al. .... 435/7.1

\* cited by examiner

*Primary Examiner*—Thurman K. Page

*Assistant Examiner*—Lakshmi Channavajjala

(74) *Attorney, Agent, or Firm*—Ezra Sutton

(57) **ABSTRACT**

Cytokine antagonists for use in localized clinical disorders are provided for the treatment and prevention of damage to the optic nerve, other cranial nerves, spinal cord, nerve roots, peripheral nerves or muscles caused by any one of the following: a herniated nucleus pulposus, osteoarthritis, other forms of arthritis, disorders of bone, disease, or trauma. The cytokine antagonists are used to treat these disorders by local administration. These cytokine antagonists include antagonists to tumor necrosis factor.

**33 Claims, No Drawings**